Crossmark

Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes

Crossref DOI link: https://doi.org/10.1038/s41598-025-15056-y

Published Online: 2025-08-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Meng

Wang, Lan

Wang, Qi

Guo, Tian-Hui

Gao, Wen

Zhang, Bi-Yuan

Wang, Hai-Ji
License Information

Text and Data Mining valid from 2025-08-20

Version of Record valid from 2025-08-20
More Information

Article History

Received: 12 March 2025

Accepted: 5 August 2025

First Online: 20 August 2025

Declarations

:

: The authors declare no competing interests.

: Not applicable.

: This study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University, China (Reference No. QYFYWZLL29747). All experiments involving human participants were conducted in accordance with the Declaration of Helsinki and institutional guidelines and regulations. Given the retrospective nature of this study, the requirement for informed consent was waived by the Ethics Committee of the Affiliated Hospital of Qingdao University.

Document is current

Any future updates will be listed below